Cullinan Associates Inc. lessened its stake in shares of Amgen, Inc. (NASDAQ:AMGN) by 0.8% during the fourth quarter, according to the company in its most recent disclosure with the SEC. The fund owned 52,185 shares of the medical research company’s stock after selling 433 shares during the quarter. Amgen makes up 0.8% of Cullinan Associates Inc.’s holdings, making the stock its 25th biggest holding. Cullinan Associates Inc.’s holdings in Amgen were worth $10,159,000 as of its most recent filing with the SEC.

Several other hedge funds and other institutional investors also recently bought and sold shares of AMGN. Deane Retirement Strategies Inc. boosted its position in Amgen by 0.6% during the fourth quarter. Deane Retirement Strategies Inc. now owns 9,838 shares of the medical research company’s stock valued at $1,915,000 after acquiring an additional 60 shares during the last quarter. Arlington Partners LLC boosted its position in Amgen by 86.7% during the fourth quarter. Arlington Partners LLC now owns 140 shares of the medical research company’s stock valued at $27,000 after acquiring an additional 65 shares during the last quarter. Murphy Capital Management Inc. boosted its position in Amgen by 2.3% during the third quarter. Murphy Capital Management Inc. now owns 11,285 shares of the medical research company’s stock valued at $2,339,000 after acquiring an additional 254 shares during the last quarter. Fairfield Bush & CO. boosted its position in Amgen by 0.8% during the second quarter. Fairfield Bush & CO. now owns 33,934 shares of the medical research company’s stock valued at $6,264,000 after acquiring an additional 260 shares during the last quarter. Finally, Mutual Advisors LLC boosted its position in Amgen by 5.8% during the second quarter. Mutual Advisors LLC now owns 4,814 shares of the medical research company’s stock valued at $889,000 after acquiring an additional 265 shares during the last quarter. 76.88% of the stock is currently owned by hedge funds and other institutional investors.

In other Amgen news, Director Tyler Jacks sold 20,000 shares of the company’s stock in a transaction dated Thursday, December 6th. The shares were sold at an average price of $195.41, for a total value of $3,908,200.00. Following the completion of the sale, the director now directly owns 28,979 shares of the company’s stock, valued at approximately $5,662,786.39. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Also, SVP Cynthia M. Patton sold 1,777 shares of the company’s stock in a transaction dated Thursday, November 29th. The stock was sold at an average price of $202.88, for a total transaction of $360,517.76. Following the completion of the sale, the senior vice president now directly owns 23,090 shares of the company’s stock, valued at $4,684,499.20. The disclosure for this sale can be found here. Corporate insiders own 0.27% of the company’s stock.

Shares of AMGN traded down $3.48 on Friday, reaching $199.20. The company’s stock had a trading volume of 111,434 shares, compared to its average volume of 3,032,399. The company has a debt-to-equity ratio of 2.05, a current ratio of 3.08 and a quick ratio of 2.84. Amgen, Inc. has a twelve month low of $163.31 and a twelve month high of $210.19. The firm has a market capitalization of $127.68 billion, a PE ratio of 15.85, a P/E/G ratio of 2.05 and a beta of 1.32.

Amgen (NASDAQ:AMGN) last posted its earnings results on Tuesday, October 30th. The medical research company reported $3.69 earnings per share for the quarter, topping the Zacks’ consensus estimate of $3.45 by $0.24. Amgen had a net margin of 9.44% and a return on equity of 54.14%. The company had revenue of $5.90 billion for the quarter, compared to analyst estimates of $5.78 billion. During the same quarter in the prior year, the business posted $3.27 EPS. The firm’s revenue was up 2.3% compared to the same quarter last year. As a group, analysts expect that Amgen, Inc. will post 14.24 EPS for the current year.

The firm also recently announced a quarterly dividend, which will be paid on Friday, March 8th. Investors of record on Friday, February 15th will be issued a $1.45 dividend. This represents a $5.80 dividend on an annualized basis and a dividend yield of 2.91%. The ex-dividend date is Thursday, February 14th. This is a positive change from Amgen’s previous quarterly dividend of $1.32. Amgen’s dividend payout ratio is currently 41.97%.

AMGN has been the topic of several research reports. Leerink Swann set a $209.00 price objective on shares of Amgen and gave the company a “hold” rating in a report on Monday, September 17th. BidaskClub upgraded shares of Amgen from a “hold” rating to a “buy” rating in a report on Wednesday, September 26th. Royal Bank of Canada set a $193.00 price objective on shares of Amgen and gave the company a “neutral” rating in a report on Friday, September 28th. Cantor Fitzgerald initiated coverage on shares of Amgen in a report on Monday, October 1st. They set a “neutral” rating and a $223.00 price objective on the stock. Finally, Zacks Investment Research upgraded shares of Amgen from a “hold” rating to a “buy” rating and set a $234.00 price objective on the stock in a report on Monday, October 1st. One research analyst has rated the stock with a sell rating, thirteen have given a hold rating, ten have issued a buy rating and one has assigned a strong buy rating to the company. Amgen currently has a consensus rating of “Hold” and a consensus target price of $205.90.

ILLEGAL ACTIVITY NOTICE: “Cullinan Associates Inc. Decreases Holdings in Amgen, Inc. (AMGN)” was posted by TheOlympiaReport and is owned by of TheOlympiaReport. If you are reading this news story on another site, it was stolen and reposted in violation of US and international copyright and trademark laws. The original version of this news story can be viewed at https://theolympiareport.com/2019/01/11/cullinan-associates-inc-decreases-holdings-in-amgen-inc-amgn.html.

About Amgen

Amgen Inc discovers, develops, manufactures, and delivers human therapeutics worldwide. It offers products for the treatment of oncology/hematology, cardiovascular, inflammation, bone health, nephrology, and neuroscience. The company's products include Evenity to treat osteoporosis in postmenopausal women; Prolia to treat postmenopausal women with osteoporosis; Xgeva for skeletal-related events prevention; Repatha to treat coronary diseases; Enbrel to treat plaque psoriasis, rheumatoid arthritis, and psoriatic arthritis; Parsabiv to treat secondary hyperparathyroidism (sHPT); and Aimovig for the prevention of migraine.

Read More: What is cost of equity?

Want to see what other hedge funds are holding AMGN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Amgen, Inc. (NASDAQ:AMGN).

Institutional Ownership by Quarter for Amgen (NASDAQ:AMGN)

Receive News & Ratings for Amgen Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Amgen and related companies with MarketBeat.com's FREE daily email newsletter.